Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging

Area of Science:

• Biochemistry
• Radiochemistry
• Nuclear Medicine

Background:

• Small molecule kinase inhibitors are a key therapeutic class, particularly in oncology.
• Radiolabeled kinase inhibitors have been developed for positron emission tomography (PET) imaging.
• The expanding coverage of the kinome suggests broader applications for in vivo PET imaging.

Purpose of the Study:

• To review the literature on radiolabeled kinase inhibitors for PET imaging between 2010 and mid-2015.
• To discuss radiotracer design, radiochemistry, biological evaluation, and imaging results.
• To explore the utility of selective vs. promiscuous scaffolds and challenges in intracellular enzyme imaging.

Main Methods:

• Literature review of studies published from 2010 to mid-2015.
• Analysis of radiotracer design and radiochemistry approaches.
• Evaluation of biological tracer studies and nuclear imaging outcomes.

Main Results:

• Early radiolabeled inhibitors, often based on tyrosine kinase inhibitor (TKI) isotopologues, have advanced to clinical trials.
• Novel radioligands targeting relevant kinases are under preclinical investigation for cancer and neuroimaging.
• The review covers diverse aspects from tracer design to imaging results.

Conclusions:

• Radiolabeled kinase inhibitors are increasingly important for PET imaging in oncology and beyond.
• Future applications include therapy monitoring and receptor density studies.
• Ongoing research focuses on novel radioligands and addressing imaging challenges.